Jasper Therapeutics, Inc. announced the appointment of Herb Cross, an experienced senior financial executive, as the company?s Chief Financial Officer (CFO). Jeet Mahal, who previously held both CFO and Chief Operating Officer (COO) roles, will continue as the company?s COO. Mr. Cross brings more than two decades of experience in financial leadership roles at both public and private biotechnology companies.

Before joining Jasper, he served as CFO at Atreca, leading its initial public offering and holding responsibility for all administrative functions, including finance, corporate communications, human resources and corporate services. Prior to Atreca, he was CFO at ARMO BioSciences, with responsibility for all administrative functions and business development, and led its initial public offering and served as CFO through the sale of the company to Eli Lilly in 2018. Mr. Cross also served as CFO and interim Chief Executive Officer at KaloBios Pharmaceuticals and was CFO at Affymax as well.

Mr. Cross began his career at Arthur Andersen, LLP, and received a Bachelor of Science in Business Administration from the Haas School of Business at the University of California, Berkeley. He is a certified public accountant, currently inactive, in the state of California. Mr. Mahal joined Jasper in December 2019 from Portola Pharmaceuticals, where he worked for 11 years and held a number of positions of increasing leadership, most recently as Vice President, Business Development and Vice President, Strategic Marketing.

He led the successful execution of multiple business development partnerships for Andexxa®, Bevyxxa® and cerdulatinib. He also played a key role in Portola Pharmaceuticals? equity financings, including its initial public offering and multiple royalty transactions.

Earlier in his career, he was Director, Business and New Product Development, at Johnson & Johnson on the Xarelto® development and strategic marketing team. He started his career in the drug development laboratories at COR Therapeutics.